GWLL (Goldenwell Biotech) Debt-to-Asset : 4.86 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GWLL Goldenwell Biotech Inc GWLL
31 GF Score
Price $0.69
! 1 Warning Sign
View Full Analysis

What is Goldenwell Biotech Debt-to-Asset?

Goldenwell Biotech GWLL -1.47% 31 Debt-to-Asset is 4.86 as of Jun. 2026. GuruFocus rates GWLL with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

Goldenwell Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.00 Mil. Goldenwell Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.14 Mil. Goldenwell Biotech's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was $0.03 Mil. Goldenwell Biotech's debt to asset for the quarter that ended in Jun. 2026 was 4.86.

Goldenwell Biotech  (OTCPK:GWLL) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Goldenwell Biotech Debt-to-Asset Related Terms

Goldenwell Biotech Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Goldenwell Biotech's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Goldenwell Biotech Debt-to-Asset Chart

Goldenwell Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial 0.10 0.10 0.42 0.43 2.67

Goldenwell Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.44 2.67 5.05 4.86

GWLL vs HAIN, BOF, LFVN: Debt-to-Asset Comparison

For the Packaged Foods subindustry, Goldenwell Biotech's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Goldenwell Biotech Debt-to-Asset vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Goldenwell Biotech's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Goldenwell Biotech's Debt-to-Asset falls into.


GWLL
31GF Score
Goldenwell Biotech Inc GWLL
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Goldenwell Biotech Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Goldenwell Biotech's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 0.096) / 0.036
=2.67

Goldenwell Biotech's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 0.141) / 0.029
=4.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 4.86 mean?
Goldenwell Biotech (GWLL) has a Debt-to-Asset of 4.86 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Goldenwell Biotech and its competitors.
Is Goldenwell Biotech's Debt-to-Asset too high?
Goldenwell Biotech's current Debt-to-Asset is 4.86. Overall, Goldenwell Biotech has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Goldenwell Biotech's Debt-to-Asset compare to HAIN and BOF?
Goldenwell Biotech's Debt-to-Asset of 4.86 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Consumer Packaged Goods company?
A good Debt-to-Asset depends on the Consumer Packaged Goods industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Goldenwell Biotech and its competitors. Goldenwell Biotech's current Debt-to-Asset is 4.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Goldenwell Biotech stock overvalued right now?
Goldenwell Biotech (GWLL) has a current Debt-to-Asset of 4.86. The current Debt-to-Asset is 4.86. Goldenwell Biotech's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Goldenwell Biotech (GWLL), the current Debt-to-Asset is 4.86 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Goldenwell Biotech Business Description

Address 581 Boston Mills Road, Suite 300, Hudson, OH, USA, 44236
Goldenwell Biotech Inc is engaged in the research and development, production, and sales of healthcare and supplement products. Its products comprise JI MAI - Bovine Cardiac Vascular Active Peptide, Double Proline AG - 3D Active Collagen Peptide, Cartilage Peptide - Type II collagen peptide, and Sugar Master.
31GF Score

Get the complete analysis for GWLL

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.69
Price